Loading…
← CockpitCompetitor Analysis › 7666.HK Metis TechBio Co., Ltd. Class HOpen in the cockpit ↗

Metis TechBio Co., Ltd. Class H7666.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Materials›Chemicals: Major Diversified

Chinese AI-powered drug-delivery biotech building lipid-nanoparticle and nanomaterial platforms (NanoForge) for new drug formulations.

≈ A Chinese Moderna-style AI/lipid-nanoparticle drug-delivery platformMomentum laggard 6
Mkt cap
$1.05B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$8.49M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-99.4 pp
WACC 5.6%
Hurdle
n/a
no reverse DCF
Next earnings
105 days
3 Mar 2027
Close · HKDHK$7.25
1D-0.4%
1W-34.9%
1M-35.2%
3M-38.1%
6M-63.8%
YTDn/a
1Yn/a
ATR %15.1%
52w lowhigh75.8% off high

What Metis TechBio does

Chinese AI-powered drug-delivery biotech building lipid-nanoparticle and nanomaterial platforms (NanoForge) for new drug formulations.

In one line: A Chinese Moderna-style AI/lipid-nanoparticle drug-delivery platform.

Products and services

  • NanoForge lipid nanoparticle platform
  • AI-driven molecule/nanomaterial design
  • Animal health & anti-aging pipeline
  • Clinical drug candidates

Customers

  • Global pharma licensing/collaboration partners

Where it sits in the supply chain

  • Biopharmaceuticals
  • AI + nanomaterial drug delivery…
  • Drug candidate development & licensing

What could go right

  • Record 2026 HK IPO proceeds fund R&D scale-up
  • Pharma partnership/licensing deals

What could go wrong

  • Early-stage/pre-revenue platform
  • Execution risk on AI drug-delivery technology

Moat: narrow (IP / patents, data, process know-how). Proprietary AI+quantum-chemistry nanomaterial design platform, but drug-delivery pipeline still early-stage.

Headquarters: China

Named competitors

Metis TechBio at a glance

Size Metis TechBio (7666.HK) is a Hong Kong Materials company (Chemicals: Major Diversified) with a market value of $1.05B, the 573rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$7.25 on 18 Nov 2026.

Performance Over six months the shares fell 63.8%, against -31.1% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 2nd lowest of 21 in its peer set.

Growth Revenue grew 6,987.0% over the last twelve months (peer median +2.1%); the operating margin is -367.1% (peer median 10.7%).

Valuation It trades at 45.2× enterprise value to sales against a peer median of 2.2× (most expensive of 21).

Capital Return on invested capital runs 99.4 points below its cost of capital (5.6% WACC).

Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).

Relative performance

40608010021 May 202621 Aug 202618 Nov 2026Peer median 727666.HK 40
Six months, rebased to 100: Metis TechBio against the median of its 20 peers (local-currency closes).

Metis TechBio financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aHK$114MHK$1.61MHK$10.3MHK$644,235
Revenue growth—+6,987%-84%+1,502%—
Gross profitn/aHK$75.2M-HK$36.2M-HK$35.3M-HK$7.93M
EBITDAn/a-HK$381M-HK$372M-HK$395M-HK$439M
Net incomen/a-HK$425M-HK$541M-HK$643M-HK$596M
Free cash flown/a-HK$152M-HK$263M-HK$267M-HK$228M
Capital expendituren/aHK$20.6MHK$3.94MHK$62.4MHK$67.3M
Total debtn/aHK$146MHK$2.49BHK$2.42BHK$753M

Quarterly statements and history in the cockpit →

Metis TechBio competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%VCT300779JUBLINGREA6032006003282143704763603360603281RPELLXS00042030064160318100258540416883593005960146807666.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Metis TechBio is the large dot.

Fundamentals: revenue growth against valuation

0%+2,000%+4,000%+6,000%0×20×40×VCT300779JUBLINGREA603200214370603360RPELLXS6883597666.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Metis TechBio is the large dot.

Metis TechBio competitors and peer comparison

Head to head with its named competitors (7666.HK vs MRNA vs 2228.HK vs ARCT)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
Metis TechBio 7666.HK$1.05B-64%+6,987%-367%45.2×n/a
Moderna MRNA$79.6B+309%+13%-116%31.2×n/a
XtalPi 2228.HK$2.87B-34%+4%-127%21.3×n/a
Arcturus Therapeutics ARCTn/a+18%n/an/an/an/a

How Metis TechBio compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Metis TechBio against its 20 peers (data as of 18 Nov 2026)
Measure7666.HKPeer medianRank in peer set
1-month return-35.2%-11.7%2nd lowest of 21
6-month return-63.8%-31.1%2nd lowest of 21
Distance from 52-week high-75.8%-46.6%3rd lowest of 21
Revenue growth (TTM)+6,987.0%+2.1%highest of 21
Operating margin-367.1%10.7%lowest of 21
EV / Sales45.2×2.2×most expensive of 21
ROIC minus cost of capital-99.4 pp-1.8 pplowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Metis TechBio 7666.HKHong Kong$1.05B-64%+6,987%-367%45.2×n/an/a
Victrex VCT.LUnited Kingdom$1.06B+46%-1%14%2.8×16.7%+1.9%
Qingdao Huicheng Environmental Technology 300779.SZChina$1.08B-48%-13%5%10.4×n/an/a
Jubilant Ingrevia JUBLINGREA.NSIndia$1.00B-19%+15%10%2.0×28.0%+44.9%
Shanghai Emperor of Cleaning Hi-Tech 603200.SSChina$1.12B-24%+4%-8%15.2×n/an/a
CNSIG Inner Mongolia Chemical Industry 600328.SSChina$1.12B-36%-20%-7%1.7×n/an/a
Caregen 214370.KSSouth Korea$982M-74%-2%20%16.8×36.8%+3.8%
Jinan Acetate Chemical 4763.TWTaiwan$1.14B-5%-24%43%1.9×-20.2%+41.2%
Dalian Bio-Chem 603360.SSChina$971M-54%0%16%5.1×8.5%+18.4%
Hubei Jianghan New Materials 603281.SSChina$1.15B-38%+8%17%2.4×3.9%+6.3%
Raghav Productivity Enhancers RPEL.NSIndia$942M+109%+38%28%27.9×n/an/a
Lanxess LXS.DEGermany$1.19B-24%-4%0%0.6×5.3%-1.5%
Jilin Chemical Fibre Stock 000420.SZChina$1.20B-34%+11%5%2.6×n/an/a
Jiangsu Zhengdan Chemical Industry 300641.SZChina$914M-29%-30%17%2.2×7.1%+11.6%
Zhejiang Huangma Technology 603181.SSChina$891M-33%+7%17%2.3×n/an/a
Jiangsu Shuangxing Color Plastic New Materials 002585.SZChina$1.27B-10%-4%-4%2.0×21.0%+0.2%
Nippon Soda 4041.TJapan$1.29B+11%0%10%1.5×5.2%+1.8%
China Resources Chemical Innovative Materials 301090.SZChina$1.30B-33%+4%1%0.5×20.6%+1.1%
Guangzhou Sanfu Newmaterials Technology 688359.SSChina$832M-54%+8%-7%10.2×n/an/a
Rianlon 300596.SZChina$1.35B-15%+11%11%1.8×n/an/a
Hanchem 014680.KSSouth Korea$1.35B-49%+11%17%2.1×5.8%+7.4%

Questions

Who are Metis TechBio's main competitors?
Named competitors: Moderna (MRNA), XtalPi Holdings (2228.HK), Arcturus Therapeutics (ARCT). The cockpit's measured peer set (industry) also includes Victrex (VCT.L), Qingdao Huicheng Environmental Technology (300779.SZ), Jubilant Ingrevia (JUBLINGREA.NS), Shanghai Emperor of Cleaning Hi-Tech (603200.SS), CNSIG Inner Mongolia Chemical Industry (600328.SS), Caregen (214370.KS).
Is Metis TechBio expensive compared with its peers?
On ev / sales it trades at 45.2× against a peer median of 2.2×, most expensive of 21 in its peer set.
How has Metis TechBio stock performed?
Over six months to 18 Nov 2026 the shares returned -63.8% against -31.1% for the median peer.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.